Advertisement Sidebar
Recent Posts
- NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024
- FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
- SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
- VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024
- VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC
Oncology Conference Videos
Oncology News
By. Terry Mamounas Date: 12/07/2023In a collaborative study between NVP and RT, led by oncologist…
By: Melinda Telli, MD, Date: 12/9/2023 At the SABCS 2023 conference, we had the privilege…
Evandro Bezerra, MD, hematologist and assistant professor at The Ohio State University Wexner Medical Center,…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab)…
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology,…
Jeff Sharman, MD, a medical oncologist at the Willamette Ballet Cancer Institute and Research Center,…
At ASH 2023, Katherine Broome, MD, a medical doctor and medical oncologist at the Georgetown…
At ASH 2023, there is a discussion with Dr. Davide Matino, Assistant Professor of Medicine at…
By: Yara Abdou, MD, Date. 12/08/2023 At SABCS 2023, Yara Abdou, MD, a medical oncologist…
At ASH 2023, Hamza Hashmi, MD, a medical doctor and hematologist from Charleston, South Carolina,…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set…